Upstream Bio is a clinical-stage company developing treatments for severe inflammatory respiratory disease. Its lead candidate, verekitug, is a monoclonal antibody that blocks the TSLP receptor—positioned as a distinctive way to interrupt upstream inflammatory signaling rather than only downstream cytokines. Programs target severe asthma, chronic rhinosinusitis with nasal polyps and COPD, aiming at patients whose disease remains poorly controlled on standard care.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0.6 | — | -27.3 | — |
| Q2 2025 | 0.9 | — | -40 | — |
| Q3 2025 | 0.7 | — | -33.8 | — |
| Q4 2025 | 0.7 | — | -42.5 | — |
| Q1 2026 | 1 | 82.7% | -40.6 | — |
| Q2 2026 | 0.8 | -17.5% | -39.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: StablecoinX Inc. (USDE), Medallion Financial Corp. (MFIN), X4 Pharmaceuticals, Inc. (XFOR), RF Acquisition Corp II (RFAI), Coincheck Group N.V. (CNCK), SCHMID Group N.V. (SHMD)